Fig. 3.

(A) Tumour biodistribution quantification shows an increase in mean percentage Injected Dose per tumour weight (%ID/g) in mice injected with [¹¹¹In]In-anti-ICAM-1 compared to [¹¹¹In]In-mIgG2a. However, there was no significant difference in [¹¹¹In]In-anti-ICAM-1 uptake in the irradiated tumours compared to the mock-treated control. (B) SPECT image VOI quantification of each xenograft tumour at each SPECT time-point of 24, 48 and 72 h shows an increase in [¹¹¹In]In-anti-ICAM-1 compared to [¹¹¹In]mIgG2a at each of the time-points. There was a small increase in signal at the 24 h time-point in untreated mice compared to irradiated mice. However, there was no difference in [¹¹¹In]In-anti-ICAM-1 signal in the irradiated tumours compared to the mock-treated control ones in the other 2 time-points. (C) Representative MIP images from the 24 h SPECT imaging study (white dashed circles indicate tumours).